In an evaluation of PCM patients who received a variety of different chemotherapy regimens, risk factors of developing MDS and subsequent AML included the use of IMiDs, older age, male gender, and a low reinfusion dose of CD34+ cells following first AHSCT [16]. The gene discussed is CD34; the disease is myelodysplastic syndrome.